Abstract

Bisoprolol (Monocor, Cyanamid; Emcor, Merck) is a new cardioselective β adrenoceptor blocking drug which is claimed to have “a distinctive pharmacokinetic and pharmacological profile, good efficacy and tolerance” and is “unlikely to adversely affect cardiovascular risk factors such as cholesterol”. Are these claims correct, and if so are they important clinically?